2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Osteochondroma
1
Exostoses, Multiple Hereditary
1
Interventions
Cyclophosphamide
910
Carboplatin
787
pembrolizumab
746
Paclitaxel
744
Bevacizumab
716
Cisplatin
708
Gemcitabine
621
Docetaxel
584
Rituximab
558
Radiotherapy
548
Dexamethasone
511
Nivolumab
491
Doxorubicin
445
Fluorouracil
392
Capecitabine
382
Etoposide
358
Pemetrexed
338
Cytarabine
335
Oxaliplatin
335
Lenalidomide
328
Prednisone
327
Erlotinib Hydrochloride
323
fludarabine phosphate
316
Trastuzumab
305
Leucovorin
299
fludarabine
296
Vincristine
288
Bortezomib
284
Filgrastim
284
Cetuximab
277
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Palovarotene
×
Clear all
NCT03442985
2022-08-01
MO-Ped
Ipsen
Phase 2
Terminated
193 enrolled
20 charts